Across TCGA pan-cancer cohorts, SKIV2L mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SKIV2L data layer compared with 26 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SKIV2L mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SKIV2L expression acts as an unfavorable survival marker, although some lineages such as OV show a favorable association.

PDAC, OV, and LSCC are the cancer types where SKIV2L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	II,III,IV	0.657	0.949	.009	19	view →
OV	DFS	Quartile	All	1.000	0.489	.046	8	view →
LSCC	DFS	Quartile	II,III,IV	0.847	1.000	.028	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: SKIV2L tumor-vs-normal RNA expression · all SKIV2L data types